TY - GEN
T1 - The eye at altitude
AU - Morris, Daniel S.
AU - Somner, John
AU - Donald, Michael J.
AU - McCormick, I. J C
AU - Bourne, R. R A
AU - Huang, Suber S.
AU - Aspinall, Peter
AU - Dhillon, Baljean
PY - 2006
Y1 - 2006
N2 - High altitude retinopathy (HAR) was first described in 1969 as engorgement of retinal veins with occasional papilloedema and vitreous hemorrhage. Since then various studies have attempted to define the incidence, etiology and significance of this phenomenon, usually with small numbers of subjects. Recently studies on relatively large groups of subjects in Nepal, Bolivia and Tibet have confirmed that the retinal vasculature becomes engorged and tortuous in all lowlanders ascending above 2500m. Sometimes this leads to hemorrhages, cotton wool spots and papilloedema, which is the pathological state better known as high altitude retinopathy. These studies have also shown a significant change in both corneal thickness and intraocular pressure at altitude. The retinal blood vessels are the only directly observable vascular system in the human body and also supply some of the most oxygen-demanding tissue, the photoreceptors of the retina. New techniques are being applied in both hypobaric chamber and field expeditions to observe changes in retinal function during conditions of hypobaric hypoxia. This work allows better advice to be given to lowlanders traveling to altitude either if they have pre-existing ocular conditions or if they suffer from visual problems whilst at altitude. This especially applies to the effect of altitude on refractive eye surgery and results of recent studies will be discussed so that physicians can advise their patients using the latest evidence. Retinal hypoxia at sea level accounts for the developed world's largest cause of blindness, diabetic retinopathy. The investigation of retinal response to hypobaric hypoxia in healthy subjects may open new avenues for treatment of this debilitating disease. © 2007 Springer Science+Business Media, LLC.
AB - High altitude retinopathy (HAR) was first described in 1969 as engorgement of retinal veins with occasional papilloedema and vitreous hemorrhage. Since then various studies have attempted to define the incidence, etiology and significance of this phenomenon, usually with small numbers of subjects. Recently studies on relatively large groups of subjects in Nepal, Bolivia and Tibet have confirmed that the retinal vasculature becomes engorged and tortuous in all lowlanders ascending above 2500m. Sometimes this leads to hemorrhages, cotton wool spots and papilloedema, which is the pathological state better known as high altitude retinopathy. These studies have also shown a significant change in both corneal thickness and intraocular pressure at altitude. The retinal blood vessels are the only directly observable vascular system in the human body and also supply some of the most oxygen-demanding tissue, the photoreceptors of the retina. New techniques are being applied in both hypobaric chamber and field expeditions to observe changes in retinal function during conditions of hypobaric hypoxia. This work allows better advice to be given to lowlanders traveling to altitude either if they have pre-existing ocular conditions or if they suffer from visual problems whilst at altitude. This especially applies to the effect of altitude on refractive eye surgery and results of recent studies will be discussed so that physicians can advise their patients using the latest evidence. Retinal hypoxia at sea level accounts for the developed world's largest cause of blindness, diabetic retinopathy. The investigation of retinal response to hypobaric hypoxia in healthy subjects may open new avenues for treatment of this debilitating disease. © 2007 Springer Science+Business Media, LLC.
KW - Altitude
KW - Corneal pachymetry
KW - High altitude retinopathy
KW - Intraocular pressure
KW - Refractive surgery
UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-33846788540&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/record.url?scp=2-s2.0-33846788540&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2-s2.0-33846788540&partnerID=8YFLogxK
U2 - 10.1007/978-0-387-34817-9-21
DO - 10.1007/978-0-387-34817-9-21
M3 - Conference contribution
SN - 9780387348162
VL - 588
T3 - Advances in Experimental Medicine and Biology
SP - 249
EP - 270
BT - Hypoxia and Exercise
ER -